Our first and most advanced project, KB103, uses our proprietary viral platform to develop an “off the shelf” treatment for Epidermolysis Bullosa (http://www.debra.org/whatiseb), which affects 1 out of every 20,000 births in the United States with no treatment or cure.

The current standard of care for DEB patients is limited to palliative treatments, as there are no known treatments which affect the outcome of the disease. Current products under development are taking an autologous approach to treating the disease, developing individualized therapies created from the patient’s own tissues. We believe that the major drawbacks of autologous therapies are the high cost of treatment, the need for sophisticated doctors and equipment, and the significant time lag between diagnosis and commencement of patient’s treatment.

Therefore, there is a critical need for an off-the-shelf reproducible product that will provide a best in class treatment for Epidermolysis Bullosa and that is what we are after.

rdeb wound